Amgen stock trades at EUR 372.83 after mixed analyst calls

Amgen (ISIN US0311621009) was trading at EUR 372.83 at Lang & Schwarz on September 30, 2026, down 0.09 percent versus the prior close of EUR 373.15. The biotechnology company announced positive topline Phase 3 results for dazodalibep on September 22, giving its pipeline a fresh clinical milestone. The market is weighing that progress against valuation and trial risks.

Pipeline adds a fresh catalyst

Amgen announced positive topline Phase 3 results for dazodalibep in moderate-to-severe systemic Sjogren's disease on September 22, 2026. The result expands the importance of the late-stage pipeline as Amgen works to offset patent expirations and competitive pressure.

MarketBeat reported that Amgen's Phase 3 OASIZ 301 trial met its primary endpoint, while another study remains necessary before a regulatory filing. That creates a clear distinction between clinical progress and a product launch that could contribute revenue.

Q2 numbers reset the baseline

Amgen reported USD 10.05 billion in revenue for Q2 2026 on August 4, 2026, up 9.5 percent from the same quarter a year earlier. EPS reached USD 6.29, beating the USD 5.62 consensus estimate by USD 0.67, according to MarketBeat.

Amgen's 2026 EPS guidance is USD 22.30-23.50, compared with the USD 22.94 full-year analyst expectation cited by MarketBeat. The comparison leaves the midpoint of guidance near the current consensus, making execution and pipeline conversion central to the next valuation step.

Targets split above the quote

Scotiabank analyst Louise Chen maintained a Sector Outperform rating and raised the price target from USD 450.00 to USD 500.00 on September 29, 2026, according to GuruFocus. By contrast, Yahoo Finance reported that HSBC downgraded Amgen to Hold and cut its target to USD 425.00 from USD 445.00.

Stock stays below yearly high

Amgen's market capitalization was USD 228.6 billion on September 30, 2026, while its 52-week range was USD 283.00 to USD 447.03. The Lang & Schwarz quote of EUR 372.83 therefore arrives alongside a large spread in analyst expectations, with clinical milestones competing against concerns about valuation and future competition.

Amgen stock was trading at EUR 372.83 at Lang & Schwarz on September 30, 2026 at 10:32 a.m. CEST, down 0.09 percent versus the prior close of EUR 373.15 on September 29, 2026.

More news and analyses on Amgen stock